DUPIXENT is licensed for use in patients 6 years and older as add-on maintenance treatment for severe asthma with Type 2 inflammation characterised by:1
raised blood eosinophils (EOS)
and/or raised fraction of exhaled nitric oxide (FeNO)
who are inadequately controlled with high-dose (ages 12 and older) and medium-to-high dose (ages 6 to 11) inhaled corticosteroids (ICS) plus another medicinal product for maintenance treatment
More than 600,000 patients have been treated with DUPIXENT worldwide as of February 2023, across indications1
DUPIXENT can be self-injected or administrated by a caregiver via a pre-filled pen or pre-filled syringe after appropriate training by a healthcare professional (HCP)2*
Dosing with DUPIXENT in different patient population2
-
-
-
100 mg is not currently available for use in the UK.
100 mg is not currently available for use in the UK.
Introducing the DUPIXENT pre-filled pen
DUPIXENT pre-filled pen can be used to ensure
patients aged 12 years and older administer DUPIXENT as directed2
DUPIXENT can be administered with a pre-filled pen (patients aged 12 years and older only) or a pre-filled syringe (patients of all ages)1,2
Learn how to administer DUPIXENT using the pre-filled pen or pre-filled syringe2
How to store DUPIXENT2
Keep the pre-filled pen(s) or pre-filled syringe(s) and all medicines out of the reach of children
Keep unused pre-filled pens or pre-filled syringes in the original carton and store in the refrigerator between 2°C and 8°C
Store pre-filled pens or pre-filled syringes in the original carton to protect it from light
Do not keep pre-filled pens or pre-filled syringes at room temperature (<25ºC) for more than 14 days2
Do not freeze the pre-filled pen or pre-filled syringe2
Do not shake the pre-filled pen or pre-filled syringe at any time2
Do not place the pre-filled pen or pre-filled syringe into direct sunlight2
Do not heat the pre-filled pen or pre-filled syringe2
Exacerbations and lung function
DUPIXENT can improve exacerbations and lung function of 12+ years old patients with severe asthma
- Data on File (patient numbers). Sanofi and Regeneron Pharmaceuticals, Inc. 2023.
- DUPIXENT Summary of Product Characteristics, 2023. Date last accessed May 2023.
- DUPIXENT Patient Information Leaflet for pre-filled pen. Available at: https://www.medicines.org.uk/emc/product/11321/pil. Date last accessed: May 2023.
- DUPIXENT Patient Information Leaflet for pre-filled syringe. Available at: https://www.medicines.org.uk/emc/product/8553/pil. Date last accessed: May 2023..
*The pre-filled pen is not intended for use in children below 12 years of age. For children 6-11 years of age the pre-filled syringe is the presentation appropriate for administration.
AD, atopic dermatitis; CRSwNP, Chronic Rhinosinusitis with Nasal Polyposis; HCP, healthcare professional; OCS, oral corticosteroids.
References
MAT-XU-2204590 (v1.0) | Date of preparation: May 2023